Targeting von willebrand factor as a novel anti-platelet therapy; Application of ARC1779, an anti-vWF aptamer, against thrombotic risk

Archives of Pharmacal Research

Volumn 35, Issue 10, 2012, Pages 1693-1699

  Bae, Ok Nam ^a  

^a Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6B4; 82D6A3; ACETYLSALICYLIC ACID; AJW 200; ALX 0081; ALX 0681; ANTICOAGULANT AGENT; ATOPAXAR; CLOPIDOGREL; EGAPTIVON PEGOL; GPG 290; PRASUGREL; TERUTOBAN; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VORAPAXAR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; NONHUMAN; RISK FACTOR; THROMBOSIS; TREATMENT OUTCOME;

ANIMALS; APTAMERS, NUCLEOTIDE; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 84872104775     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-1000-3     Document Type: Article

References (51)

1. Arzamendi, D., Dandachli, F., Théorêt, J. F., Ducrocq, G., Chan, M., Mourad, W., Gilbert, J. C., Schaub, R. G., Tanguay, J. F., and Merhi, Y., An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis. Clin. Appl. Thromb. Hemost., 17, E70-E78 (2011).
2. Barrett, N. E., Holbrook, L., Jones, S., Kaiser, W. J., Moraes, L. A., Rana, R., Sage, T., Stanley, R. G., Tucker, K. L., Wright, B., and Gibbins, J. M., Future innovations in anti-platelet therapies. Br. J. Pharmacol., 154, 918-939 (2008).
3. Blann, A. D., Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb. Haemost., 95, 49-55 (2006).
4. Bongers, T. N., de Maat, M. P., van Goor, M. L., Bhagwanbali, V., van Vliet, H. H., Gómez García, E. B., Dippel, D. W., and Leebeek, F. W., High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke, 37, 2672- 2677 (2006).
5. Bouchard, P. R., Hutabarat, R. M., and Thompson, K. M., Discovery and development of therapeutic aptamers. Annu. Rev. Pharmacol. Toxicol., 50, 237-257 (2010).
6. Cataland, S. R., Peyvandi, F., Mannucci, P. M., Lämmle, B., Kremer Hovinga, J. A., Machin, S. J., Scully, M., Rock, G., Gilbert, J. C., Yang, S., Wu, H., Jilma, B., and Knoebl, P., Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am. J. Hematol., 87, 430-432 (2012).
7. Cauwenberghs, N., Meiring, M., Vauterin, S., van Wyk, V., Lamprecht, S., Roodt, J. P., Novák, L., Harsfalvi, J., Deckmyn, H., and Kotzé, H. F., Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler. Thromb. Vasc. Biol., 20, 1347-1353 (2000).
8. Chen, L., Bracey, A. W., Radovancevic, R., Cooper, J. R., Jr., Collard, C. D., Vaughn, W. K., and Nussmeier, N. A., Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg., 128, 425-431 (2004).
9. Clemetson, K. J. and Clemetson, J. M., Platelet GPIb complex as a target for anti-thrombotic drug development. Thromb. Haemost., 99, 473-479 (2008).
10. Cosmi, B., ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. Curr. Opin. Mol. Ther., 11, 322-328 (2009).
11. Davi, G. and Patrono, C., Platelet activation and atherothrombosis. N. Engl. J. Med., 357, 2482-2494 (2007).
12. De Meyer, S. F., Stoll, G., Wagner, D. D., Kleinschnitz, C., De Meyer, S. F., Stoll, G., Wagner, D. D., and Kleinschnitz, C., Stroke, 43, 599-606 (2012).
13. Diener, J. L., Daniel Lagassé, H. A., Duerschmied, D., Merhi, Y., Tanguay, J. F., Hutabarat, R., Gilbert, J., Wagner, D. D., and Schaub, R., Inhibition of von Willebrand factormediated platelet activation and thrombosis by the antivon Willebrand factor A1-domain aptamer ARC1779. J. Thromb. Haemost., 7, 1155-1162 (2009).
14. Firbas, C., Siller-Matula, J. M., and Jilma, B., Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev. Cardiovasc. Ther., 8, 1689-1701 (2010).
15. Gawaz, M., Langer, H., and May, A. E., Platelets in inflammation and atherogenesis. J. Clin. Invest., 115, 3378-3384 (2005).
16. Gilbert, J. C., DeFeo-Fraulini, T., Hutabarat, R. M., Horvath, C. J., Merlino, P. G., Marsh, H. N., Healy, J. M., Boufakhreddine, S., Holohan, T. V., and Schaub, R. G., First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation, 116, 2678-2686 (2007).
17. Gresele, P., Momi, S., and Falcinelli, E., Anti-platelet therapy: phosphodiesterase inhibitors. Br. J. Clin. Pharmacol., 72, 634-646 (2011).
18. He, S., Cao, H., Magnusson, C. G., Eriksson-Berg, M., Mehrkash, M., Schenck-Gustafsson, K., and Blombäck, M., Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr- 843Met of the von Willebrand factor protein. Thromb. Res., 103, 241-248 (2001).
19. Huang, R. H., Fremont, D. H., Diener, J. L., Schaub, R. G., and Sadler, J. E., A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. Structure, 17, 1476-1484 (2009).
20. Jackson, S. P. and Schoenwaelder, S. M., Anti-platelet therapy: in search of the 'magic bullet'. Nat. Rev. Drug Discov., 2, 775-789 (2003).
21. Jilma, B., Paulinska, P., Jilma-Stohlawetz, P., Gilbert, J. C., Hutabarat, R., and Knöbl, P., A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb. Haemost., 104, 563-570 (2010).
22. Jilma-Stohlawetz, P., Gilbert, J. C., Gorczyca, M. E., Knöbl, P., and Jilma, B., A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb. Haemost., 106, 539-547 (2011a).
23. Jilma-Stohlawetz, P., Gorczyca, M. E., Jilma, B., Siller- Matula, J., Gilbert, J. C., and Knöbl, P.., Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb. Haemost., 105, 545-552 (2011b).
24. Jilma-Stohlawetz, P., Knöbl, P., Gilbert, J. C., and Jilma, B. B., The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb. Haemost., 108, 284-290 (2012).
25. Keefe, A. D. and Schaub, R. G., Aptamers as candidate therapeutics for cardiovascular indications. Curr. Opin. Pharmacol., 8, 147-152 (2008).
26. Kiefer, T. L. and Becker, R. C., Inhibitors of platelet adhesion. Circulation, 120, 2488-2495 (2009).
27. Knöbl, P., Jilma, B., Gilbert, J. C., Hutabarat, R. M., Wagner, P. G., and Jilma-Stohlawetz, P., Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion, 49, 2181-2185 (2009).
28. Lenting, P. J., Pegon, J. N., Groot, E., and de Groot, P. G., Regulation of von Willebrand factor-platelet interactions. Thromb. Haemost., 104, 449-455 (2010).
29. Mackman, N., Triggers, targets and treatments for thrombosis. Nature. 45, 914-918 (2008).
30. Markus, H. S., McCollum, C., Imray, C., Goulder, M. A., Gilbert, J., and King, A., The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke, 42, 2149-2153 (2011).
31. Mayr, F. B., Knobl, P., Jilma, B., Siller-Matula, J. M., Wagner, P. G., Schaub, R. G., Gilbert, J. C. and Jilma- Stohlawetz, P., The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion, 50, 1079-1087 (2010).
32. Michelson, A. D., Anti-platelet therapies for the treatment of cardiovascular disease. Nat. Rev. Drug Discov., 9, 154-169 (2010).
33. Nesbitt, W. S., Westein, E., Tovar-Lopez, F. J., Tolouei, E., Mitchell, A., Fu, J., Carberry, J., Fouras, A. and Jackson, S. P., A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat. Med., 15, 665-673 (2009).
34. Nichols, W. L., Hultin, M. B., James, A. H., Manco-Johnson, M. J., Montgomery, R. R., Ortel, T. L., Rick, M. E., Sadler, J. E., Weinstein, M., and Yawn, B. P., von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia, 14, 171-232 (2008).
35. Noris, P. and Balduini, C. L., Investigational drugs in throm botic thrombocytopenic purpura. Expert Opin. Investig. Drugs, 20, 1087-1098 (2011).
36. Raju, N. C., Eikelboom, J. W. and Hirsh, J., Platelet ADPreceptor antagonists for cardiovascular disease: past, present and future. Nat. Clin. Pract. Cardiovasc. Med., 5, 766-780 (2008).
37. Rayes, J., Hommais, A., Legendre, P., Tout, H., Veyradier, A., Obert, B., Ribba, A. S., and Girma, J. P., Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J. Thromb. Haemost., 5, 321-328 (2007).
38. Reininger, A. J., VWF attributes - impact on thrombus formation. Thromb. Res., 122 Suppl 4, S9-S13 (2008).
39. Ruggeri, Z. M., The role of von Willebrand factor in thrombus formation. Thromb. Res., 120 Suppl 1, S5- S9 (2007).
40. Sadler, J. E., Biomedicine. Contact-how platelets touch von Willebrand factor. Science, 297, 1128-1129 (2002).
41. Sadler, J. E., Budde, U., Eikenboom, J. C., Favaloro, E. J., Hill, F. G., Holmberg, L., Ingerslev, J., Lee, C. A., Lillicrap, D., Mannucci, P. M., Mazurier, C., Meyer, D., Nichols, W. L., Nishino, M., Peake, I. R., Rodeghiero, F., Schneppenheim, R., Ruggeri, Z. M., Srivastava, A., Montgomery, R. R., and Federici, A. B., Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J. Thromb. Haemost., 4, 2103-2114 (2006).
42. Scarborough, R. M., Kleiman, N. S., and Phillips, D. R., Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation, 100, 437-444 (1999).
43. Siller-Matula, J. M., Krumphuber, J., and Jilma, B., Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br. J. Pharmacol., 159, 502-517 (2010).
44. Sostres, C. and Lanas, A., Gastrointestinal effects of aspirin. Nat. Rev. Gastroenterol. Hepatol., 8, 385-394 (2011).
45. Spiel, A. O., Mayr, F. B., Ladani, N., Wagner, P. G., Schaub, R. G., Gilbert, J. C. and Jilma, B., The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets, 20, 334-340 (2009).
46. Varga-Szabo, D., Pleines, I., and Nieswandt, B., Cell adhesion mechanisms in platelets. Arterioscler. Thromb. Vasc. Biol., 28, 403-412 (2008).
47. Vischer, U. M., von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J. Thromb. Haemost., 4, 1186-1193 (2006).
48. von Willebrand, E. A., Hereditärpseudohemofili. Fin. Laekaresaellsk Hand. 68, 87-112. (1926).
49. Wagner, D. D. and Burger, P. C., Platelets in inflammation and thrombosis. Arterioscler. Thromb. Vasc. Biol., 23, 2131- 2137 (2003).
50. Weitz, J. I., Hirsh, J., and Samama, M. M., New antithrombotic drugs: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest, 133, 234S-256S (2008).
51. Yago, T., Lou, J., Wu, T., Yang, J., Miner, J. J., Coburn, L., López, J. A., Cruz, M. A., Dong, J. F., McIntire, L. V., McEver, R. P., and Zhu, C., Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J. Clin. Invest., 118, 3195-3207 (2008).